Beranda › Kanker Paru Non-Sel Kecil › Illinois › Bloomington
Uji klinis Kanker Paru Non-Sel Kecil di Bloomington, IL
11 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar Bloomington (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Menerima pesertaFase 3
- Illinois CancerCare-Bloomington, Bloomington
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Menerima pesertaFase 2
- OSF Saint Joseph Medical Center, Bloomington
- Illinois CancerCare-Bloomington, Bloomington
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Menerima pesertaFase 3
- Illinois CancerCare-Bloomington, Bloomington
- Carle BroMenn Medical Center, Normal · 2 mi jauhnya
- Carle Cancer Institute Normal, Normal · 2 mi jauhnya
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Menerima pesertaFase 3
- Illinois CancerCare- Bloomington, Bloomington
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Illinois CancerCare - Bloomington, Bloomington
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Menerima pesertaFase 2
- Illinois CancerCare-Bloomington, Bloomington
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Illinois CancerCare-Bloomington, Bloomington
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Illinois CancerCare-Bloomington, Bloomington
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Illinois CancerCare-Bloomington, Bloomington
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2/3
- Illinois CancerCare-Bloomington, Bloomington
- Carle BroMenn Medical Center, Normal · 2 mi jauhnya
- Carle Cancer Institute Normal, Normal · 2 mi jauhnya
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Menerima pesertaStudi observasional
- Illinois CancerCare-Bloomington, Bloomington
- Carle Cancer Institute Normal, Normal · 2 mi jauhnya
Uji klinis Kanker Paru Non-Sel Kecil di kota lain
- Houston, TX145 studi
- New York City, NY120 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH56 studi
- Washington, DC55 studi
Studi lain di Bloomington
- Kanker Paru9 studi
- Kanker Prostat7 studi
- Kanker Kolorektal7 studi
- Karsinoma Sel Skuamosa Kepala dan Leher6 studi
- Kanker Pankreas5 studi
- Melanoma5 studi
- Kanker Hipofaring5 studi
- Kanker Laring5 studi
- Kanker Mulut5 studi
- Kanker Payudara5 studi
- Kanker Ginjal (Karsinoma Sel Renal)4 studi
- Leukemia Mieloid Akut4 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.